סך נכסי הפעילות העסקית ProQR Therapeutics N.V. (PRQR)

This chart of the price action for ProQR Therapeutics N.V. (PRQR) total assets, valued at 157.06, demonstrates the financial standing of the RNA drug developer. ProQR Therapeutics N.V. (PRQR) aims for global leadership by expanding its product portfolio through the Axiomer system and alliances with major industry players. Intellectual capital and gene-editing patents secure future licensing revenues. Despite the risks of clinical trial failures, the liquidity deficit is currently mitigated.

ProQR Therapeutics N.V. (PRQR) is actively investing in the robotization of RNA oligonucleotide synthesis and the automation of precision screening. Total assets reflect the aggregate of equity and debt, reconstructed via the reverse method through ROA profitability. The trend in gross assets visualizes the actual volume of resources available for scaling laboratory infrastructure. Analysis of this metric allows for an assessment of the company's financial stability when deploying high-tech production complexes.